Identification of biomarkers for the early detection of non-small cell lung cancer: a systematic review and meta-analysis
- 8 December 2023
- journal article
- review article
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 45 (1-2) , 1-22
Abstract
Lung cancer (LC) causes few symptoms in the earliest stages, leading to one of the highest mortality rates among cancers. Low-dose computerised tomography (LDCT) is used to screen high-risk individuals, reducing the mortality rate by 20%. However, LDCT results in a high number of false positives and is associated with unnecessary follow-up and cost. Biomarkers with high sensitivities and specificities could assist in the early detection of LC, especially in patients with high-risk features. Carcinoembryonic antigen (CEA), cytokeratin 19 fragments and cancer antigen 125 have been found to be highly expressed during the later stages of LC but have low sensitivity in the earliest stages. We determined the best biomarkers for the early diagnosis of LC, using a systematic review of eight databases. We identified 98 articles that focussed on the identification and assessment of diagnostic biomarkers and achieved a pooled area under curve of 0.85 (95% CI 0.82–0.088), indicating that the diagnostic performance of these biomarkers when combined was excellent. Of the studies, 30 focussed on single/antigen panels, 22 on autoantibodies, 31 on miRNA and RNA panels, and 15 suggested the use of circulating DNA combined with CEA or neuron-specific enolase (NSE) for early LC detection. Verification of blood biomarkers with high sensitivities (Ciz1, exoGCC2, ITGA2B), high specificities (CYFR21-1, antiHE4, OPNV) or both (HSP90α, CEA) along with miR-15b and miR-27b/miR-21 from sputum may improve early LC detection. Further assessment is needed using appropriate sample sizes, control groups that include patients with non-malignant conditions, and standardised cut-off levels for each biomarker.Keywords
Funding Information
- University of Hull
This publication has 139 references indexed in Scilit:
- Variant Ciz1 is a circulating biomarker for early-stage lung cancerProceedings of the National Academy of Sciences, 2012
- EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assaysTumor Biology, 2012
- A Multiplexed Serum Biomarker Immunoassay Panel Discriminates Clinical Lung Cancer Patients from High-Risk Individuals Found to be Cancer-Free by CT ScreeningJournal of Thoracic Oncology, 2012
- Serum microRNA Biomarkers for Detection of Non-Small Cell Lung CancerPLOS ONE, 2012
- Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodulesBMC Cancer, 2011
- A multi-analyte serum test for the detection of non-small cell lung cancerBritish Journal of Cancer, 2010
- Early detection of lung adenocarcinoma in sputum by a panel of microRNA markersInternational Journal of Cancer, 2010
- Sources of Bias in Specimens for Research About Molecular Markers for CancerJournal of Clinical Oncology, 2010
- Altered miRNA expression in sputum for diagnosis of non-small cell lung cancerLung Cancer, 2010
- Carcinoembryonic Antigen and CD44 Variant Isoforms Cooperate to Mediate Colon Carcinoma Cell Adhesion to E- and L-selectin in Shear FlowJournal of Biological Chemistry, 2008